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Liver fibrosis reflects sustained liver injury often frommultiple, simultaneous factors.Whilst
the presence of mild fibrosis on biopsy can be a reassuring finding, the identification of
advanced fibrosis is critical to the management of patients with chronic liver disease.
This necessity has lead to a reliance on liver biopsy which itself is an imperfect test and
poorly accepted by patients. The development of robust tools to non-invasively assess
liver fibrosis has dramatically enhanced clinical decision making in patients with chronic
liver disease, allowing a rapid and informed judgment of disease stage and prognosis.
Should a liver biopsy be required, the appropriateness is clearer and the diagnostic yield
is greater with the use of these adjuncts. While a number of non-invasive liver fibrosis
markers are now used in routine practice, a steady stream of innovative approaches
exists. With improvement in the reliability, reproducibility and feasibility of these markers,
their potential role in disease management is increasing. Moreover, their adoption into
clinical trials as outcome measures reflects their validity and dynamic nature. This review
will summarize and appraise the current and novel non-invasive markers of liver fibrosis,
both blood and imaging based, and look at their prospective application in everyday
clinical care.
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INTRODUCTION
As the gateway to the systemic circulation from the gut, the liver performs several critical functions,
coordinating substrate metabolism, and detoxification as well as responding to immune stimuli.
Its unique position and vascular supply also leaves it constantly exposed to potential injury, and
liver damage, induced by hepatotoxins such as viral hepatitis, alcohol or excess fat, leads to a cycle
inflammation and fibrosis. This process involves the deposition of extracellular matrix (ECM),
which if degraded results in repair and regeneration; however should the source of liver injury
persist, fibrosis may progress, and ultimately evolve to cirrhosis or end-stage liver disease.
Historically, the role of liver biopsy was both for diagnostic and staging purposes. Given the
ability to diagnose the majority of liver conditions with blood testing alone, liver biopsy now
primarily serves to quantify fibrosis in order to stage disease. This informs the clinician and
patient regarding the urgency of initiating therapy (where possible) and prognosis. Indeed, recent
longitudinal studies have demonstrated the presence and severity of fibrosis on biopsy as the single
most important predictor of outcome in NAFLD, the commonest cause of liver disease in the
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Western world, highlighting the need for disease staging for an
individual patient (Angulo et al., 2015; Ekstedt et al., 2015).
Liver biopsy represents the “gold standard” for the assessment
and quantification of liver fibrosis. However, its invasiveness
engenders pain and significant potential complications, leading
to poor patient acceptance (Cadranel et al., 2000). Other
disadvantages include considerable cost (Pasha et al., 1998), and
its inherent shortcomings related to sampling error and sample
quality from needle biopsy specimens (Sherlock, 1962; Villeneuve
et al., 1996; Bedossa et al., 2003; Merriman et al., 2006) have lead
to questions regarding its suitability as the reference standard for
liver fibrosis (Standish et al., 2006; Bedossa and Carrat, 2009).
These factors, along with an acknowledgement of the need to
stage disease without reliance on liver biopsy, have lead to an
exponential interest in the identification and use of non-invasive
markers of liver fibrosis.
The performance of a non-invasive marker of fibrosis is
measured using liver biopsy staging of fibrosis as the reference
standard. This is typically reported by sensitivity and sensitivity
measurements, as well as an area under the receiver operating
curve (AUROC) value, which indicates the ability of the
marker (at different cut-offs) to correctly classify a patient
into a particular category of fibrosis. Values of <0.7, 0.7−0.8,
0.8−0.9, and >0.9 indicate poor, fair, good, and excellent
accuracy, respectively. Serum non-invasive tests can potentially
achieve a perfect AUROC value, having been developed and
calibrated using liver biopsy as a reference. The same is
not true for imaging-based modalities, who are unable to
achieve excellent diagnostic accuracy for fibrosis, an important
point to consider when interpreting studies (Tsochatzis et al.,
2011a). Another issue relates to “spectrum bias,” where different
stages of liver fibrosis may be represented unequally within
a candidate study, leading to potentially misleading results,
highlighting the importance of independent validation of
markers.
Non-invasive markers of fibrosis are being incorporated into
the routine clinical care of patients with liver disease, although
the field continues to evolve. The importance of these markers
comes with the stark realization that standard liver biochemistry
is of little value in determining the severity of liver fibrosis in
primary care (Armstrong et al., 2012). Instead, simple scores
based on blood test results can enable a tier system whereby
primary care physicians can determine the need for specialist
referral for patients (Sheron et al., 2012). With the availability
of accurate non-invasive tests, the ability to screen large cohorts
for significant liver disease is now becoming a possibility,
allowing the assessment of the true burden of liver disease
in the general population (Koehler et al., 2016). Moreover, as
novel anti-fibrosis therapies enter clinical trials, robust non-
invasive markers are crucial to allow effective trial design and
obviate the need for multiple, invasive liver biopsies to assess
efficacy.
In this review, the types and application of several blood-based
non-invasive markers of liver fibrosis are described, followed by
a thorough description of current ultrasound based elastography
methods and their utility in staging of liver disease. Finally,
magnetic resonance imaging techniques to improve staging of
liver fibrosis and cirrhosis are considered.
NON-INVASIVE SEROLOGICAL MARKERS
Whilst there have been many non-invasive biomarkers
investigated and proposed, an ideal serological test for
liver fibrosis which reduces the need to perform invasive
investigations such as liver biopsy is still awaited. This ideal
serological test would be quick to perform and analyse as well as
inexpensive and reproducible. Furthermore, an ideal test would
be able to distinguish between distinct entities in liver pathology
such as inflammation and fibrosis, be unaffected by impairment
in liver function, as well as being able to predict and track disease
progression or regression.
When evaluating potential biomarkers, there is a need to
ensure consistency in assessment and evaluation, and the related
need for simple and robust classification systems (Veidal et al.,
2010). This is important as the various serological biomarkers for
liver fibrosis described in the medical literature to date have been
appraised and validated in differing liver disease contexts, and so
in different cohorts of patients. The majority of studies published
have been performed in patients with hepatitis C (HCV), with
fewer studies performed in patients with hepatitis B (HBV), non-
alcoholic fatty liver disease (NAFLD), and alcoholic liver disease
(ALD), with fewer still reported in rarer conditions such as in
autoimmune liver diseases and hereditary haemochromatosis. As
one may expect, these biomarkers perform differently in these
differing liver disease contexts. As such, care must be taken to
ensure that use of a specific biomarker test at individual patient
level has both diagnostic and clinical validity in the context of the
patient’s illness (Balistreri, 2014). It is equally important to note
that most of the biomarkers described in the literature work best
in predicting established or advanced fibrosis when compared
to the gold standard of liver biopsy, and that biomarkers
generally do not perform well in indeterminate stages of liver
disease.
To help aid understanding, non-invasive biomarkers of
fibrosis may be broadly divided into two classes. Class I markers
are direct serum markers reflecting ECM turnover and/or
fibrogenic changes at cellular level in the liver. Class II markers
of fibrosis are indirect serum markers based on algorithms and
mathematical model of varying complexity and derived from
changes that occur in liver function (Gressner et al., 2007; Veidal
et al., 2010).
Class I (Direct) Biomarkers of Liver Fibrosis
Class I biomarkers are direct markers of fibrosis and reflect the
molecular pathogenesis and turnover of liver ECM. The main
source of fibrosis in the liver is derived from hepatic stellate cells
(HSCs) and myofibroblasts (Korner et al., 1996; Friedman, 2000;
Rockey and Friedman, 2006; Gressner et al., 2007; Henderson
et al., 2013). Injury to the liver leads to the production of
cytokines and to the activation of HSCs initially causing liver
inflammation, and then to potentially irreversible change and
scarring within the ECM tissue architecture.
Class I markers may be subcategorized into enzymatic
markers, collagen (and related) markers, Glycoproteins and
matrix-metalloproteinase markers, and Glycosaminoglycan
markers (Table 1; Guechot et al., 1996; Murawaki et al., 1999;
Walsh et al., 1999; McHutchison et al., 2000; Gressner et al.,
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2007). Of these various classes, collagen derived markers and
glycosaminoglycans (hyaluronic acid) have proven to be themost
widely utilized in the development of new fibrosis biomarkers.
Few class I markers are used in routine clinical practice as
they largely do not directly correlate with whole tissue or body
function and so provide data of limited clinical value. As such,
their turnaround time is higher, availability is limited to mainly
research and specialist settings and investigational costs are
generally increased when compared to class II markers. Another
limitation is that class I markers are neither all liver derived nor
liver specific and so serum measurements do not always directly
relate to liver activity. For example, during infection, where
acute systemic inflammation co-exists, these markers may also
be affected and their absolute values can reflect both fibrinolytic
as well as fibrogenic activity.
Class II (Indirect) Biomarkers of Liver
Fibrosis
Class II biomarkers provide an indirect reflection of liver ECM
activity and fibrosis through the measurement of liver function
or injury. As these tests reflect alterations in hepatic function
and often correlate with signs and symptoms of illness, they are
well established and used routinely in clinical practice to both
diagnose and to monitor liver disease.
The broad range of activities the liver performs includes
thermostasis, energy balance, carbohydrate, fat and protein
metabolism, haemocoagulation, iron and hemoglobin
metabolism, immune balance, production of bile acids and
hormones, and clearance of toxins (Pratt and Kaplan, 2000;
Limdi and Hyde, 2003; Tan et al., 2012; Neuman et al., 2014).
Therefore, the number of class II biomarkers that may be tested
is extensive.
In daily clinical practice, serological testing for liver function
may be broadly categorized into the following categories:
− Liver enzymes, including alanine amino transferase (ALT),
aspartate amino transferase (AST), alkaline phosphatase
(ALP), and gamma glutamyl transferase (GGT)
− Markers of synthetic function, such as prothrombin time
(PT/INR), bilirubin, haptoglobin, albumin, Apolipoprotein
A1, α2-macroglobulin, ceruloplasmin, transferrin and
hepcidin
− Other indirectly measured markers, such as platelet count,
α1-antitrypsin, ferritin, and certain adipokines (adiponectin
and leptin; Ding et al., 2005).
As one may expect, although class II markers are more readily
available and generally more cost-effective to employ, as proxy
markers for fibrosis, their results are not as reliable or accurate
as class I markers (Adams et al., 2005). Serum levels of these
markers may be affected by a wide range of factors. It is well
recognized that ALT levels, commonly thought to indicate the
severity of liver disease, are wholly unreliable as a predictor
of fibrosis (McCormick et al., 1996) and often within normal
range in individuals with advanced disease (Mofrad et al., 2003).
Indeed, one recent paper demonstrated a 56% prevalence of
NAFLD in 103 volunteers with type 2 diabetes who had normal
plasma aminotransferase levels (Portillo-Sanchez et al., 2015).
Combination or Panel Non-invasive
Biomarkers
Whilst individual biomarkers have value as described, the
combination of various biomarkers—with varying degrees of
complexity—can greatly improve the sensitivity and specificity
of these tests. Simple combination tests broadly employ class II
biomarkers to indirectly assess liver fibrosis. The simplest of these
is the AST/ALT ratio. Afdhal and Nunes summarized a number
of studies that assessed its value, with most of these studies
undertaken in patients with HCV reporting sensitivities between
53–78% and specificities between 90 and 100% for detecting liver
fibrosis (Afdhal and Nunes, 2004). Another simple test is the AST
to platelet ratio index (APRI), which uses the platelet count in
addition to AST to predict fibrosis, first described in 2003 by
Wai and colleagues in patients with HCV (Wai et al., 2003). The
APRI score has also been shown to have some value in patients
with HBV and PBC, although not in ALD, probably due to the
confounding effects of alcohol on platelet suppression (Lieber
et al., 2006; Loaeza-del-Castillo et al., 2008; Umemura et al., 2015;
Xiao et al., 2015). Other simple indirect combination markers
include the PGA (prothrombin time, γ-glutamyl transferase and
apolipoprotein A1) and PGAA (PGA plus α-2 macroglobulin)
indices, Pohl score and Forn’s Index (Imbert-Bismut et al., 2001;
Pohl et al., 2001; Forns et al., 2002). Another simple combination
panel is the NAFLD fibrosis score (NFS), an easily accessible
TABLE 1 | Examples of Class I (direct) serum non-invasive biomarkers for liver fibrosis.
References References
Metalloproteinases (MMPs) Murawaki et al., 1999; Walsh et al.,
1999
Transforming growth factor (TGF)-β Flisiak et al., 2002
Tissue inhibitors of
metalloproteinases (TIMPs)
Walsh et al., 1999 Microfibril-associated protein 4 (MFAP4) Molleken et al., 2009
Hyaluronic acid (HA) Guechot et al., 1996 N Glycans- profiles Molleken et al., 2009
Laminin Korner et al., 1996 Procollagen type III amino-terminal peptide (PIIINP) Guechot et al., 1996
Chitinase-3-like protein 1
(CHI3L1 or YKL-40)
Berres et al., 2009
Collagen IV, VI Shahin et al., 1992; Yabu et al., 1994;
George et al., 1999
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online score which can be used by general practitioners to triage
patients with suspected NAFLD in order to determine the need
for referral for specialist assessment (Angulo et al., 2007). The
AUROC values, sensitivities, specificities, and predictive values
of these tests where available for liver fibrosis are provided in
Table 2.
More complex combination biomarkers involve a panel of
tests or complex algorithms, some of which are patented in the
assessment liver fibrosis. These include the Fibrotest/Fibrosure R©,
Fibrometer R©, and Hepascore R© (Imbert-Bismut et al., 2001;
Adams et al., 2005; Cales et al., 2005). As these tests generally
include some class I markers as well as class II markers (Table 2),
they have enhanced diagnostic accuracy, however this comes
at an increased cost and reduced test availability in some
cases, while also demanding greater physician time and effort
to calculate and subsequently to interpret. Nevertheless, as
these panels continue to improve, they are gaining increased
acceptance in clinical practice, and large longitudinal studies
have demonstrated their ability to predict prognosis and liver-
related outcomes. For example, the Fibrometer R© and FIB-4
showed good ability to predict significant liver-related events
[AUROC values of 0.88 (0.83–0.91) and 0.87 (0.81–0.92)]
in 373 patients with HCV over a median 9.5 year follow
up, better than that predicted by fibrosis grade (Boursier
et al., 2014). The Enhanced Liver Fibrosis (ELF) test similarly
demonstrated prognostic capabilities in 457 patients with chronic
liver disease followed a median over 7 years to predict
death and clinical outcomes (Parkes et al., 2010). Moreover, a
number of studies have now shown the value of the simpler
investigations such as the NFS, the FIB-4 and APRI not only
in the assessment of liver fibrosis, but also in estimating
prognosis (Vallet-Pichard et al., 2007; Treeprasertsuk et al., 2013;
Vergniol et al., 2014; Xiao et al., 2015). These findings are
important considerations for the application of non-invasive
markers with well-validated diagnostic and prognostic ability
as outcome measures in clinical trials, obviating the need
for repeated liver biopsies thereby enhancing recruitment and
study efficiency. In routine clinical practice, the use of these
scores alone or in combination can also significantly reduce
the need for a liver biopsy, increasing the appropriateness
and diagnostic yield from the remaining biopsies that are
performed. For instance, Sebastiani and co-workers found that
the combination of the APRI test with the Fibrotest-Fibrosure
in 2035 patients with chronic HCV infection reduced the need
for liver biopsy in 50–80% of cases, with high (>90%) diagnostic
accuracy for significant fibrosis and cirrhosis (Sebastiani et al.,
2009).
In summary, the quest to find an ideal non-invasive serological
biomarker or combination ofmarkers to diagnose and predict the
outcome of liver fibrosis is ongoing, with considerable progress
made over the past decade. Nevertheless, these investigations
remain imperfect, particularly for the detection of intermediate
fibrosis grades, and require judicious use tailored to the
individual case, and detailed understanding to ensure their use
is valid. As these investigations continue to be refined and
improved, the need for staging liver biopsy will continue to
decline over time.
NON-INVASIVE ULTRASOUND
ELASTOGRAPHY
Ultrasound Based Elastography for the
Assessment of Liver Fibrosis
Ultrasound based elastography has revolutionized the assessment
of liver fibrosis over the last decade. The concept of elastography
for the assessment of fibrosis is simple and stems from applying
an external force to soft tissue, compressing the tissue, and
thereby generating a shear wave which can be measured (Ophir
et al., 1991). The speed of the shear wave propagating through
the tissue corresponds to the tissue elasticity based on Young’s
modulus and hence, the amount of tissue fibrosis (Sandrin et al.,
2003).
To date, a number of different types of ultrasound based
elastography methods have been developed to assess liver
fibrosis and diagnose cirrhosis (Thiele et al., 2015). One can
broadly distinguish these elastography methods into two main
groups: one-dimensional ultrasound elastography—transient
elastography (TE); or two-dimensional (or B-mode) ultrasound
which utilizes conventional ultrasound imaging - acoustic
radiation force impulse (ARFI) imaging or point shear wave
elastography (pSWE), real-time elastography (RTE), and real-
time 2D shear wave elastography (2D-SWE). It is likely that some
of these ultrasound-based elastography instruments will improve
in time with the advent of novel technology.
Elastography measures tissue stiffness. Assessing liver fibrosis
with ultrasound-based elastography only measures a small
component of tissue stiffness. Many other factors can affect liver
tissue stiffness and have been shown to affect the accuracy of
assessing liver fibrosis with elastography. These factors were
initially studied in TE and include: Inflammation from acute
hepatitis (Arena et al., 2008a; Oliveri et al., 2008; Sagir et al.,
2008); cholestasis from biliary tract obstruction (Millonig et al.,
2008); blood congestion due to hepatic outflow obstruction and
portal hypertension(Millonig et al., 2010; Shi et al., 2013); and
food intake (Mederacke et al., 2009; Arena et al., 2013; Berzigotti
et al., 2013) Another example that elastography measures more
than just tissue fibrosis is the utilization of elastography to
measure spleen stiffness in patients with cirrhosis; where spleen
stiffness correlates with hepatic venous pressure gradient (HVPG;
Colecchia et al., 2012; Sharma et al., 2013; Takuma et al.,
2013) and reduces after liver transplantation (Chin et al., 2015).
Although not studied extensively in other ultrasound-based
elastography methods, all of these factors are thought to apply
when interpreting liver stiffness measurements obtained with
newer techniques (Bota et al., 2013a; Popescu et al., 2013).
Transient Elastography
Transient elastography (Fibroscan R©, Echosens, Paris) is the
first ultrasound-based elastography developed and is now a
well-established non-invasive method of diagnosing and staging
hepatic fibrosis (Sandrin et al., 2003). TE utilizes a mono-
dimensional ultrasound to determine liver stiffness by measuring
the velocity of low frequency elastic shear waves propagating
through the liver. TE can be performed in a short time (typically
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less than 5min) and has excellent intra- and inter- observer
variability (Fraquelli et al., 2007; Boursier et al., 2008).
The Fibroscan R© probe consists of a 3.5 MHz ultrasound
transducer installed on the axis of a low amplitude vibrator
(frequency of 50Hz and amplitude of 2mm peak-to-peak). To
obtain liver stiffness measurements, the tip of the ultrasound
transducer is placed in the right intercostal area, at the level of
the right lobe of liver. When activated, the vibrator generates an
elastic shear wave to the liver while the ultrasound transducer
performed a series of ultrasound acquisitions (transmission/
reception) with a repeat frequency of 4 kHz. A median value of
at least 10 successful measurements with an Interquartile range
(IQR) of ≤30% from the median and success rate of ≥60%, were
considered as reflective of the liver stiffness or shear modulus of
the liver. This value is expressed in kilopascals (kPa).
TE has been extensively studied for the assessment of fibrosis
in many chronic liver diseases, particularly viral hepatitis. The
two index studies on TE correlated liver stiffness with the degree
of fibrosis (METAVIR staging) on liver biopsy due to chronic
HCV infection (Castéra et al., 2005; Ziol et al., 2005). Since
then, a number of comparable studies in HCV validated this
finding (Coco et al., 2007; Arena et al., 2008b; Lupsor et al.,
2009; Wang et al., 2009; Degos et al., 2010; Zarski et al., 2012;
Afdhal et al., 2015), and a meta-analysis had reported excellent
diagnostic accuracy for HCV-related cirrhosis with an AUROC
of 0.95 (0.87–0.99; Shaheen et al., 2007). Similar studies were
performed for patients with chronic HBV (Oliveri et al., 2008;
Chan et al., 2009; Kim et al., 2009; Marcellin et al., 2009; Wang
et al., 2009; Degos et al., 2010; Sporea et al., 2010; Cardoso et al.,
2012; Goyal et al., 2013; Afdhal et al., 2015) and co-infection
with HCV/HIV (de Lédinghen et al., 2006; Vergara et al., 2007;
Kirk et al., 2009; Sánchez-Conde et al., 2010; Castera et al.,
2014), with good correlation between liver stiffness and fibrosis.
Furthermore, liver stiffness by TE has been shown to predict
liver fibrosis in ALD (Nahon et al., 2008; Nguyen-Khac et al.,
2008), NAFLD (Nobili et al., 2008; Yoneda et al., 2008; Lupsor
et al., 2010; Wong et al., 2010a; Petta et al., 2011) and chronic
cholangitides (notably, PBC and PSC; Corpechot et al., 2006,
2012). The diagnostic performance of TE have been confirmed by
several meta-analyses to show excellent diagnostic accuracy for
cirrhosis of (>90%), but only good accuracy for fibrosis (>80%;
Shaheen et al., 2007; Friedrich-Rust et al., 2008; Stebbing et al.,
2010; Tsochatzis et al., 2011b; Chon et al., 2012; Table 3).
Point Shear Wave Elastography/Acoustic
Radiation Force Impulse Imaging
pSWE (Elastography point quantification, ElastPQTM, Phillips)
and ARFI imaging (Virtual touch tissue quantificationTM,
Siemens) are ultrasound-based elastography techniques which
utilize B-mode ultrasound. This elastography technique can
be incorporated into conventional ultrasound platforms, such
as the iU22xMATRIX by Philips (Amsterdam, Netherlands)
and Acuson S2000/3000 by Siemens Healthcare (Erlangen,
Germany). Hitachi Aloka (Tokyo, Japan) also recently
announced their pSWE method known as Shear Wave
Measurement in the Radiological Society of North America TA
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Meeting in November 2015. pSWE/ARFI measures the speed of
shear waves generated by acoustic pulses that lead to localized
displacements of liver tissue (Nightingale et al., 2002). Liver
stiffness measurement with pSWE/ARFI is performed at the right
lobe of the liver, through the intercostal space, at the same site as
TE. After selecting a region of interest, at a depth of 2–8 cm with
B-mode ultrasound, the shear-wave velocity is measured within
the defined region by using ultrasound tracking beams laterally
adjacent to the single push beam (Friedrich-Rust et al., 2009).
Similar to TE, pSWE/ARFI have good intra- and inter-observer
agreement, with an intra-class correlation coefficient of between
0.84 and 0.87 (Boursier and Cales, 2010; Bota et al., 2012).
pSWE/ARFI has been described in many studies to be
comparable to TE (Friedrich-Rust et al., 2009; Lupsor et al., 2009;
Yoneda et al., 2010; Ebinuma et al., 2011; Piscaglia et al., 2011;
Rifai et al., 2011; Sporea et al., 2012). Like TE, pSWE/ARFI is able
to diagnose cirrhosis more accurately than significant fibrosis.
Several meta-analyses of pSWE/ARFI confirmed good diagnostic
accuracy for significant fibrosis, with mean AUROC of 0.84 to
0.87 and excellent diagnostic accuracy for cirrhosis of 0.91–0.94
(Friedrich-Rust et al., 2012; Bota et al., 2013a; Nierhoff et al., 2013;
Guo et al., 2015). Based on data from these meta-analyses, the
suggested cut-off values for the diagnosis of significant fibrosis
were 1.30–1.35 m/s and for cirrhosis, the values were 1.80–1.87
m/s. A recent meta-analysis of pSWE/ARFI in NAFLD reported
good diagnostic accuracy of pSWE/ARFI in assessing significant
fibrosis in patients with NAFLD (AUROC of 0.898; Liu et al.,
2015; Table 3).
Real-Time Elastography
RTE is a qualitative assessment of liver stiffness. For RTE, strain
elastography is provided either by the operator applying manual
compression (Friedrich-Rust et al., 2008) or compression is
applied by the transmitted heartbeat (Koizumi et al., 2011). The
reflected ultrasound echoes between the states of compression
can be computed to measure displacement within each location
of the tissue. Hence, the harder the tissue, the lower the amount
of displacement of reflected ultrasound echoes before and under
compression. A number of quantitative methods for RTE have
been described to improve the comparability of this elastography
technique, which include the elastic ratio, elastic index, elasticity
score, and Liver Fibrosis Index (Friedrich-Rust et al., 2007;
Kanamoto et al., 2009; Tatsumi et al., 2010; Koizumi et al., 2011;
Colombo et al., 2012; Ferraioli et al., 2012a; Fujimoto et al.,
2013; Yada et al., 2013). The basis of these quantitative methods
for RTE is to provide a ratio of stiffness or elasticity. When
comparing RTE to other ultrasound elastography methods, a
recent meta-analysis reported lower diagnostic accuracy with
RTE for significant liver fibrosis and cirrhosis, compared to TE
or ARFI (Kobayashi et al., 2015). The marked heterogeneity of
RTE studies was reported as one of the main reasons for lower
diagnostic performance of RTE.
Real-Time 2D Shear Wave Elastography
Real time 2D-SWE is a relatively new ultrasound elastography
method, which combines the initiation of a radiation force
in tissue with focused ultrasonic beams and acquisition of
transiently propagating resultant shear waves in real-time with
a high-frequency ultrasound imaging sequence (Muller et al.,
2009). In 2D-SWE, a large color coded elastography map is
generated by combining several shear waves over time with
rapid ultrasound acquisition (Thiele et al., 2016). 2D-SWE is
performed quite similarly to pSWE/ARFI. Both the size and
location of the region of interest can be chosen by the operator.
Although different to pSWE/ARFI in technology, 2D-SWE is
similar to pSWE/ARFI for the clinical user as it is implemented
on a commercial B-mode ultrasound platform (Aixplorer R©,
Supersonic Imaging, Aix en Provence, France).
Liver stiffness measured by 2D-SWE has been shown to
correlate with the stages of hepatic fibrosis on liver biopsy in
chronic HCV (Ferraioli et al., 2012b), chronic HBV (Leung et al.,
2013; Zeng et al., 2014), and alcohol-related liver disease (Thiele
et al., 2016). In mixed cohorts of patients with chronic liver
disease, several studies have shown similar results (Cassinotto
et al., 2014; Jeong et al., 2014; Bota et al., 2015; Deffieux et al.,
2015; Gerber et al., 2015; Grgurevic et al., 2015; Samir et al., 2015).
There is now increasing evidence that 2D-SWE is a comparable
elastography method to TE and pSWE/ARFI (Bavu et al., 2011;
Ferraioli et al., 2012a; Leung et al., 2013; Cassinotto et al., 2014;
Bota et al., 2015; Gerber et al., 2015; Thiele et al., 2016), although
no published meta-analysis confirming these findings exists, as
yet.
Comparative Performance of Ultrasound
Based Elastography
Based on data from published literature on elastography, the
diagnostic performance for significant fibrosis and cirrhosis
for TE, pSWE/ARFI and probably 2D-SWE are equivalent.
In contrast, RTE has a slightly lower diagnostic accuracy
and remains limited to centers with experience with this
method (Kobayashi et al., 2015). The diagnostic accuracy
(AUROC values) for significant fibrosis using TE, pSWE/ARFI
and 2D-SWE ranges between 0.65–0.97, 0.77–0.94, and 0.82–
0.99 respectively, with excellent results consistently seen for
cirrhosis, ranging between 0.80–0.99, 0.87–0.99, and 0.87–0.99,
respectively. One advantage of TE is that it can be performed
at the point of care, whereas second-generation elastrography
techniques tend to require operators trained in ultrasound,
reducing accessibility.
The failure rate of TE has been reported to range from 2.7
to 3.1% in obtaining any measurement, and 11.6 to 15.8% in
acquiring unreliable results (Castéra et al., 2010; Wong et al.,
2011). For pSWE/ARFI (Bota et al., 2013b) and 2D-SWE (Leung
et al., 2013; Poynard et al., 2013; Elkrief et al., 2015), the
failure rate for acquiring reliable results has been reported to be
significantly lower than TE. Liver stiffness measured with 2D-
SWE can be expressed either in kPa at a wide range of values
(2–150 kPa) or in the form of shear wave velocity, in m/s. One
of the main limitations of ARFI is the narrow range of shear
wave velocity measurements of 0.5–4.4 m/s, in contrast to the
range of TE of 2.5–75 kPa. This is thought to limit the ability of
ARFI to define discriminative cut-off values for certain stages of
fibrosis.
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Quality criteria for liver stiffness measurements have
previously been emphasized for TE to provide consistent and
reproducible results. These criteria are less clear for pSWE/ARFI
and 2D-SWE. The manufacturer of TE recommends that at least
10 successful liver stiffness measurements are acquired with an
IQR of ≤30% from the median, and a success rate of ≥60%.
The median value is taken as representative of liver stiffness. For
pSWE/ARFI, most studies emulate the quality criteria of TE,
where 10 valid measurements are performed and the median
value deemed as the representative measure. Unreliable results
for pSWE/ARFI were defined as an IQR/liver stiffness of greater
than 30%. In both TE and pSWE/ARFI, a single shear wave
is emitted temporarily at a single frequency for each measure.
Hence, maintaining these quality criteria is fundamental to
consistent measure of liver stiffness.
For 2D-SWE, these quality criteria do not apply. In 2D-SWE,
the ultrasound transducer emits a plurality of pulse waves at
increasing depth, using a very wide frequency band ranging from
60 to 600Hz (Bercoff et al., 2004; Muller et al., 2009). The 2D-
SWE transducer synchronously evaluate the velocity of several
shear wave fronts over a wide frequency range. A real-time color
coded map of elasticity is generated and is superimposed on the
standard B-mode image. By selecting a region of interest in the
center of the color map, the calculated value is the average of
many values within the area (Cassinotto et al., 2014). Therefore,
the quality criteria for 2D-SWE are not identical. Although
not defined, a number of 2D-SWE studies have suggested the
following: standard deviation/median ratio <0.1–0.3 and depth
of measurement <5.6 cm; stable viscoelasticity map for at least
3 s with a homogenous color in the region of interest of at
least 15mm; and 3 measurements with the mean calculated as
representative or using the median when >6 measurements are
acquired (Sporea et al., 2013; Yoon et al., 2014; Procopet et al.,
2015; Thiele et al., 2016).
Similar to serum biomarkers, ultrasound-based elastography
is excellent for the non-invasive diagnosis of cirrhosis but only
modestly good for significant fibrosis. When comparing TE with
serum biomarkers, a number of studies have shown that both TE
and serum biomarkers have equivalent performance for detecting
significant fibrosis in HCV (Castéra et al., 2005; Degos et al.,
2010; Zarski et al., 2012). Conversely, TE performs better than
serum biomarkers for detecting cirrhosis due to HCV, if TE
measurement is possible (lower applicability of TE compared to
serum biomarkers, 80 vs. 95%; Degos et al., 2010; Zarski et al.,
2012). While algorithms combining TE with serum biomarkers
improve diagnostic accuracy in assessing fibrosis, particularly
in HCV patients (Wong et al., 2010b; Boursier et al., 2011,
2012; Zarski et al., 2012), this strategy do not increase the
overall diagnostic accuracy for detecting cirrhosis (Castéra et al.,
2009; Boursier et al., 2011; Zarski et al., 2012). Furthermore,
the combination of TE with serum fibrosis biomarkers is often
advocated to better inform the clinician, allowing an informed
judgment regarding the need for liver biopsy, for example where
concordance exists in extremes of fibrosis, or discordance in
intermediate stages.
Several studies have demonstrated that liver stiffness
measured by ultrasound based elastography could predict
clinical hepatic decompensation, liver related complication and
prognosis (de Lédinghen et al., 2006; Robic et al., 2011; Vergniol
et al., 2011; Corpechot et al., 2012; Merchante et al., 2012; Pang
et al., 2014). Although a number of reports have described good
correlation between liver stiffness and HVPG (Vizzutti et al.,
2007; Bureau et al., 2008; Lemoine et al., 2008), the correlation
between clinically significant portal hypertension and liver
stiffness becomes less significant for HVPG values of >12mmHg
(Vizzutti et al., 2007). One potential explanation is that as
cirrhosis progresses, the mechanism for portal hypertension is
thought to be less dependent on intrahepatic resistance, and
more dependent of the resultant hyperdynamic circulation
and splanchnic vasodilatation (Reiberger et al., 2012). At
present, ultrasound based elastography cannot replace HVPG
for evaluation of portal hypertension or upper gastrointestinal
endoscopy for detecting oesophageal varices. However, TE is an
invaluable tool to risk stratify patients with clinically significant
portal hypertension and identify patients at risk of developing
HCC (Latinoamericana, 2015).
NON-INVASIVE MAGNETIC RESONANCE
IMAGING
Magnetic Resonance Techniques for Liver
Fibrosis Assessment
Magnetic resonance (MR) imaging techniques are attractive tools
for liver fibrosis assessment. In contrast to ultrasound techniques,
MR allows deep penetration into tissues, and unlike computed
tomography avoids ionizing radiation. Repeated assessments can
therefore be performed, without safety concerns. Furthermore,
MR can assess the whole liver, eliminating sampling errors and
can provide additional information on anatomy. There is now
extensive experience in the use of MR for the evaluation of
diffuse liver disease due to liver fat or iron deposition. Both
magnetic resonance imaging (MRI) and magnetic resonance
spectroscopy (MRS) were found to be more accurate than
histological assessment by a pathologist or by morphometry.
(Roldan-Valadez et al., 2010; Raptis et al., 2012) MR has been
used to study the epidemiology of NAFLD (Browning et al., 2004;
Szczepaniak et al., 2005; Wong et al., 2012) and more recently it
has been used as a surrogate end-point in two NAFLD clinical
trials (Le et al., 2012; Loomba et al., 2015). MR techniques are
also regarded as the gold standard for quantification of liver
iron as they have shown an excellent inverse association with
biochemically quantified hepatic iron concentration (Gandon
et al., 2004; St Pierre et al., 2005). More recently, MR techniques
for the assessment of liver fibrosis have been developed and have
produced some promising results.
Magnetic Resonance Elastography
Similar to ultrasound based elastography techniques, magnetic
resonance elastography (MRE) can determine liver stiffness by
analysis of mechanical waves propagating through the liver. The
technique requires the positioning of an external passive driver
on the patient’s body adjacent to the liver. The passive driver is
connected to a pneumatic active driver placed outside the scanner
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room which generates the mechanical waves that are propagated
through the liver.
MRE for Liver Fibrosis Evaluation
In a large prospective single center study of 96 patients with
mixed liver disease aetiologies (63%HCV; 8%NAFLD),MRE had
excellent diagnostic accuracy for the differentiation of all stages of
fibrosis, with an area under the receiver operating characteristic
curve (AUROC) for ≥F3 and F4 of 0.99 and 1.00 respectively.
(Huwart et al., 2008) Similar results have been obtained in
patients with chronic HBV and HCV, (Ichikawa et al., 2012;
Venkatesh et al., 2014a) and MRE was also shown to be closely
related to morphometric quantification of liver fibrosis (r = 0.78;
p < 0.001; Venkatesh et al., 2014b). In a meta-analysis of 697
individual patient data from 12 studies, MRE was found to have
a good diagnostic performance for all stages of liver disease (with
excellent accuracy in advanced disease; AUROC for ≥F3 and F4
of 0.93 and 0.92, respectively; Singh et al., 2015). A separate meta-
analysis of 13 studies containing 989 patients (but not individual
patient data) found pooled AUROC of 0.96 and 0.98 for the
diagnosis of fibrosis stage ≥F3 and F4 respectively (Su et al.,
2014). Despite these promising results, some concerns still exist
regarding the true diagnostic accuracy of MRE, as some of the
studies suffer from spectrum bias due to underrepresentation of
patients with intermediate stages of fibrosis. For example, the
distribution of fibrosis stages in one study was: F0 (n = 28), F1
(n = 12), F2 (n = 6), F3 (n = 6), F4 (n = 20; Wang et al., 2011).
MRE for the Evaluation of NALFD
MRE was found to be useful in the assessment of fibrosis
in patients with NAFLD, with AUROC 0.92 and 0.89 for the
diagnosis of fibrosis stage≥F3 and F4 respectively (Loomba et al.,
2014). Mixed results have been reported for use of MRE in the
diagnosis of non-alcoholic steatohepatitis (NASH). Animal and
retrospective human studies (Salameh et al., 2009; Chen et al.,
2011), have shown some promise, although in a prospective
study, MRE only had a modest diagnostic accuracy for NASH
(AUROC of 0.73; Loomba et al., 2014).
Predictive Value of MRE in Patients with Cirrhosis
A recent study examined the value of MRE in predicting clinical
outcomes in 430 patients with cirrhosis, with follow up data
on 167 patients whose cirrhosis decompensated during the
study. The authors showed that liver stiffness (LS) measured
by MRE was independently associated with the presence of
decompensation at baseline. Furthermore, a liver stiffness ≥5.8
kPa was a significant risk for decompensation (hazard ratio 4.96;
95%CI 1.4-17.0) in patients who had compensated liver disease at
baseline (Asrani et al., 2014).
Diffusion Weighted Imaging
Diffusion weighted imaging (DWI) is a magnetic resonance
technique that quantifies the diffusion of water molecules in
tissues, and this is quantified as the apparent diffusion coefficient
(ADC). The rationale for using this technique to assess liver
fibrosis is that the deposition of collagen fibers in the liver
would inhibit water diffusion, therefore leading to a decrease
in the ADC. There is now considerable experience with this
imaging technique, and a meta-analysis of 10 studies reporting
the performance of DWI compared to histology, reported pooled
AUROCs of 0.86, 0.83, and 0.86 for the diagnosis of any fibrosis
(F1-4), significant fibrosis (F2-4) and bridging fibrosis (F3-
4), respectively (Wang et al., 2012). This technique has not
seen widespread application as it has been demonstrated that
confounding factors like steatosis and perfusion also affect the
ADC (Luciani et al., 2008; Leitao et al., 2013). Furthermore, when
compared with other MR biomarkers of liver fibrosis, DWI was
inferior to MRE (Wang et al., 2012) and T1 mapping (Cassinotto
et al., 2015), and only equivalent to transient elastography and
serum based biomarkers (Lewin et al., 2007).
T1 Relaxometry
T1 relaxation time is a physical property of atoms that
varies according to their electrochemical environment. The
T1 relaxation time of hydrogen atoms in water molecules is
longer that the T1 relaxation time of hydrogen atoms in long
hydrocarbon chains like fatty acids. Therefore measuring T1 can
provide information about tissue composition. The observation
that T1 differed between healthy and diseased livers was made in
very early studies of the clinical applicability of MR in visceral
organs (Smith et al., 1981; Doyle et al., 1982). Despite this
initial promise and subsequent studies in humans that showed
some accuracy in the diagnosis of cirrhosis, T1 imaging was
largely developed for the anatomical assessment of the liver and
particularly for the evaluation of liver tumors.
The confounding effects of iron (The Clinical NMR Group,
1987; Hoad et al., 2015) and inflammation / oedema (Chamuleau
et al., 1988) on liver T1 measures have limited the application
of this technique until recently. The current impetus to
develop non-invasive assessments of liver disease, combined with
enhanced MRI methodologies, have resulted in improvements
in the performance of liver T1 as a biomarker of fibrosis, with
some exciting results. Examples of studies examining the role of
T1 relaxometry for the assessment of liver fibrosis are outlined in
Table 4.
Combination of T1 Relaxation Time with Other
Non-invasive Biomarkers
In the study by Hoad et al. (2015) liver T1 is proposed as
a biomarker of liver inflammation, which together with liver
T2
∗ for liver iron quantification and the ELF panel for fibrosis
(William et al., 2004), are combined in a decision tree to
determine who should be referred for liver biopsy. This approach
resulted in a sensitivity of 90%, specificity of 71%, positive
predictive value of 72% and negative predictive value of 89% in
identifying those with significant fibrosis or inflammation.
Dynamic Contrast Enhanced MRI
Dynamic contrast enhanced (DCE)MRI requires the intravenous
injection of hepatocyte specific gadolinium contrast agents
like gadoxetic acid (Gd-EOB-DTPA; Primovist©; Bayer, Berlin,
Germany). This technique gives an estimate of liver function,
and has been shown to differentiate between healthy controls
and patients with cirrhosis, and between the cirrhosis severity
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TABLE 4 | T1 relaxometry for the assessment of liver disease.
Study Study design Patients Main findings
Smith et al., 1981 HV vs. patients with diffuse liver
disease
HV (n = 15) Longer T1 in cirrhosis and CAH
Cirrhosis (n = 5)
CAH* (n = 1)
Doyle et al., 1982 HV vs. patients with diffuse liver
disease
HV (n = 12) Longer T1 in cirrhosis
Cirrhosis (n = 10)
The Clinical NMR Group, 1987 T1 vs. histology Patients with suspected parenchymal
disease (n = 55)
Tendency toward longer T1 in
cirrhosis/hepatitis
Thomsen et al., 1990 HV vs. disease controls vs. cirrhosis HV (n = 7) Longer T1 in cirrhosis
Disease controls (n = 17) No association with histology
T1 vs. histology in a subset
Cirrhosis (n = 15)
Histology subset(n = 10)
Keevil et al., 1994 HV vs. patients with diffuse liver
disease
HV (n = 42) Longer T1 in patients with cirrhosis and
CAH
Liver disease (n = 44)
Heye et al., 2012 HV vs. cirrhosis HV (n = 31) T1 longer in cirrhosis
Cirrhosis (n = 61)
Kim et al., 2012 Non cirrhotic patients vs. CHB
cirrhosis
Non cirrhotic patients (n = 92) T1 shorter in cirrhosis
HBV cirrhosis (n = 87)
Cassinotto et al., 2015 HV vs. cirrhosis HV (n = 40) T1 longer in cirrhosis
Cirrhosis (n = 89)
Hoad et al., 2015 T1 vs. histology Training cohort (n = 64) AUROC for cirrhosis 0.92
Validation cohort (n = 46)
AUROC for advanced fibrosis 0.81
HV, healthy volunteers; CAH, chronic active hepatitis; HBV, hepatitis B virus; AUROC, area under the receiver operating characteristic curve.
*Chronic active hepatitis is a historical term used to describe a hepatitis of unknown etiology, now believed to be chronic hepatitis C and is no longer used in clinical practice.
assessed by Child-Pugh stage or MELD score (Haimerl et al.,
2013, 2014; Nilsson et al., 2013; Verloh et al., 2014; Zhao et al.,
2015). Retrospective studies have also shown good accuracy for
the diagnosis of NASH (AUROC 0.85; Bastati et al., 2014), and
for the assessment of fibrosis (Feier et al., 2013; Ding et al., 2015).
Furthermore, in a study by Feier et al. fibrosis was the only
independent histological predictor of the relative T1 change on
DCE MRI (Feier et al., 2013).
Multi-Parametric MR Protocols
Combinations of several techniques for liver fibrosis assessment
have also been examined. In a retrospective study of patients
who had undergone liver MR, the combination of parameters
derived fromDWI, DCEMRI and susceptibility weighed imaging
resulted in improved diagnostic accuracy for the classification of
fibrosis (AUROC for F0 vs. F1-4: 0.95; F0-1 vs. F2-4: 0.95; F0-2
vs. F3-4: 0.90; F0-3 vs. F4: 0.93; Feier et al., 2016). Incorporation
of MR texture analysis techniques with other MR modalities has
also produced some promising early results (House et al., 2015;
Wu et al., 2015).
Iron Corrected T1
Liver iron is one of the major confounders in the use of
liver T1 as a biomarker of liver fibrosis, as discussed above.
One innovation that has led to improved diagnostic accuracy
for liver T1 was the development of the liver “iron corrected
T1” (cT1), which removes the confounding effect of iron from
the T1 measurements making it much more widely applicable
(Tunnicliffe et al., 2014). In a prospectively recruited cohort of
patients undergoing liver biopsy for the assessment of fibrosis,
cT1 showed excellent diagnostic accuracy against the Ishak
staging system of fibrosis with an AUROC of 0.94 for the
diagnosis of patients with any degree of fibrosis (F0 vs. F ≥ 1;
Banerjee et al., 2014). Furthermore, liver cT1 was used to derive
the liver inflammation and fibrosis (LIF) score, a standardized
continuous (0–4) score recently shown to predict liver related
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clinical outcomes, and is thus of potential use in predicting
prognosis in patients with chronic liver disease (Pavlides et al.,
2016).
Molecular MR Imaging
Molecular MR imaging represents a unique implementation of
MR technology to visualize biological processes at the cellular
and molecular level. Studies examining these technologies
are still restricted to animal models and it remains to
be seen whether they are safe and clinically applicable in
humans.
Type I collagen is a major constituent of liver fibrosis. As
it deposited in the extracellular space, it is an ideal target for
molecular MR imaging. A molecular probe (EP-3533) to type
I collagen has been developed, and is the most extensively
studied probe in molecular MR imaging of liver fibrosis. When
injected, this probe leads to shortening of the T1 relaxation
time. In a feasibility study (Polasek et al., 2012), animals with
fibrosis were found to have greater signal intensity compared
to controls (0.55 vs. 0.39; p < 0.05) when imaged after EP-
3533 injection. Furthermore, EP-3533 content measured in the
sacrificed animals had a strong correlation with Ishak staging
(r = 0.79 to 0.84 depending on the animal model). A subsequent
study demonstrated that EP-3533 was superior to other MR
biomarkers of fibrosis (T1 relaxation time, T1ρ, DWI and
magnetisation transfer techniques; Fuchs et al., 2013). In their
latest study, the group used a clinical scanner and showed that
the technique can be useful in monitoring therapeutic effects
using the bile duct ligation animal model of fibrosis (Farrar et al.,
2015). Control animals, or animals that responded to rapamycin
developed less fibrosis and had lower enhancement after EP-3533
compared to animals that did not receive or did not respond to
treatment.
CONCLUSION
In summary, this review serves to provide a reference for the
application of both serum and imaging based non-invasive
markers of liver fibrosis. The use of these important clinical
adjuncts has been discussed in detail, although given the
plethora of non-invasive markers reported in the literature, the
authors have specifically focused on the most well-known and
available tools. While serum based algorithms and established
elastography methods are being validated in large clinical
cohorts of different liver diseases and demonstrate important
predictive power in detecting liver related outcomes, imaging
methodologies evolve apace, with promising novel approaches
giving simultaneous diagnostic, staging as well as prognostic
information entering the non-invasive arena.
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